Ex Vivo Biodistribution of Mice Receiving 89Zr-Bevacizumab and 111In-Bevacizumab
| 24 h (n = 5) | 72 h (n = 5) | 168 h (n = 5) | ||||
|---|---|---|---|---|---|---|
| Biodistribution | 89Zr-Bev. | 111In-Bev. | 89Zr-Bev. | 111In-Bev. | 89Zr-Bev. | 111In-Bev. |
| Heart | 3.43 ± 0.99 | 4.34 ± 1.22 | 2.31 ± 0.93 | 3.60 ± 0.95 | 2.11 ± 0.66 | 3.09 ± 1.30 |
| Blood | 9.54 ± 5.12 | 11.87 ± 6.19 | 5.60 ± 3.20 | 8.50 ± 1.84 | 3.75 ± 2.24 | 5.99 ± 2.01 |
| Lung | 6.22 ± 4.39 | 7.58 ± 4.86 | 3.50 ± 1.57 | 5.24 ± 1.88 | 2.75 ± 0.84 | 3.56 ± 0.89 |
| Liver | 5.01 ± 1.27 | 4.91 ± 0.95 | 3.98 ± 1.29 | 5.17 ± 1.22 | 3.93 ± 1.49 | 3.30 ± 0.59 |
| Kidney | 3.94 ± 0.91 | 4.35 ± 1.01 | 2.51 ± 0.93 | 3.36 ± 0.56 | 2.45 ± 0.44 | 2.82 ± 0.63 |
| Stomach | 2.01 ± 0.25 | 2.37 ± 0.40 | 1.33 ± 0.50 | 1.94 ± 0.66 | 1.15 ± 0.45 | 1.30 ± 0.36 |
| Pancreas | 1.83 ± 0.30 | 2.33 ± 0.35 | 0.99 ± 0.42 | 1.49 ± 0.27 | 0.93 ± 0.17 | 1.06 ± 0.19 |
| Spleen | 4.52 ± 1.92 | 5.74 ± 2.76 | 3.22 ± 1.41 | 5.13 ± 2.91 | 6.07 ± 4.80 | 6.37 ± 4.54 |
| Small intestine | 3.24 ± 2.11 | 4.10 ± 2.72 | 1.54 ± 0.99 | 2.40 ± 1.79 | 2.03 ± 1.86 | 1.91 ± 1.35 |
| Large intestine | 2.09 ± 0.45 | 2.57 ± 0.64 | 1.12 ± 0.41 | 1.64 ± 0.60 | 1.63 ± 1.12 | 1.48 ± 0.64 |
| Muscle | 1.02 ± 0.16 | 1.23 ± 0.15 | 0.60 ± 0.23 | 0.90 ± 0.08 | 0.61 ± 0.20 | 0.82 ± 0.38 |
| Bone | 3.00 ± 0.87 | 3.05 ± 0.77 | 2.77 ± 1.93 | 2.29 ± 1.17 | 5.75 ± 4.01 | 2.48 ± 1.49 |
| Brain | 0.33 ± 0.09 | 0.41 ± 0.11 | 0.21 ± 0.09 | 0.31 ± 0.05 | 0.22 ± 0.06 | 0.26 ± 0.09 |
| Tumor | 4.85 ± 1.55 | 6.23 ± 2.03 | 4.36 ± 2.80 | 6.17 ± 1.30 | 6.97 ± 2.41 | 7.74 ± 1.99 |
Bev. = bevacizumab.
Data presented as %ID/g ± SD.